SynNotch receptors that identify particular priming antigens in GBM (53), such as the highly tumour-specific GBM neoantigen EGFRvIII or the CNS tissue-specific antigen myelin oligodendrocyte glycoprotein (MOG), can be employed to homogeneously trigger CAR production in tumors. This evidence concerns the gene OMG and glioblastoma.